Text

Amend 10 to License 50-19913-01 for Ketchikan General Hosp, Amending License in Entirety
	ML20205Q854
Person / Time
Site:	03019521
Issue date:	03/10/1986
From:	Thomas R; NRC OFFICE OF INSPECTION & ENFORCEMENT (IE REGION V)
To:	;
Shared Package
ML20205Q860	List: ML20205Q854; ML20205Q862;
References
	50-19913-01, 50-19913-1, NUDOCS 8606050002
	Download: ML20205Q854 (4)
	v • d • e

.

f

.rm 374 ,

&

^ETT

1

4 _PAGESj

NRCFr

!

,

PAGE

OF

(3 833

U.S. NUCLEAR REGULATORY CoMMISSloN

MATERIALS LICENSE

Amendment No. 10

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93 - 438), and Title 10

Code of Federal Regulations, Chapter I, Parts 30,31,32,33,34,35,40 and 70, and in reliance on statements and representations y

heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, ty

source, and special nuclear material designated below; to use such material for the purpose (s) and at the place (s) designated below; to E

deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This @

license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is

,

subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any g

conditions specified below,

lg

i

1

Licensee

iN

In accordance with letters

'N

dated March 4, 1986

lEj

1.

Ketchikan General Hospital

3. License number 50-19913-01 is amended in

its entirety to read as follows:!g

li

2.

3100 Tongass Avenue

!l

4. Expiration date January 31, 1987

E

Ketchikan, A!aska 99901

s

1

5. Docket or

g

Reference No.

030-19521

,

6. Byproduct, source, and/or

7. Chemical and/or physical

_8. Maximum amount that licensee

i

'

form

4may possess at any one time

I

special nuclear material

s

unde; this license

N

,;a

l

. A.

Any byproduct materidl

A.

Any radiopharmaceutical

A.,:As necessary for uses

listed in Groups I and

~ listed in Groups I and 11

\\ authorized in

p

11 of Schedule A,.

of Schedule A, Section

' Subitem 9.A.

y

Section 35.100 of ~

35.100 of'10 CFR 35'

p

~

10 CFR 35

!

_ ' ,

H

,

',

i

-

~

,

B.

Any byproduct material

x B .'

Any forn listed in Group 111' 11. ^f2curiesofeach

I

listed in Group III-

~

of Schedule A, Section 35.100

byproduct material

l

of Schedule A,

of-10 CFR<35

," authorized in

y

Section 35.100 of

Subi tem 6.B.

i

10 CFR 35

/

i

N

C.

Any byproduct material * [C.

Any

C.

3 millicuries of each

I

listed in Section 31.11(a)

byproduct material

>

h

of 10 CFR 31

-

authorized in

-

Subitem 6.C.

b

i

D.

Xenon 133

D.

Gas or gas in solution that

D.

50 millicuries

i

jl

is the subject of an active

(i .e. , not wi thdrawn or

y

terminated) "New Drug

g

Application" (NDA) approved

p

by FDA or an active (i.e.,

il

not withdrawn, terminated or

I

on " clinical hold") " Notice of

I

Claimed Investigational Exemption

f

for a New Drug" (IND) that has

y

been accepted by FDA

p

>

E.

Phosphorus 32

E.

foluble phosphate

E.

10 millicuries

N

lN

h

86060S0002 860310

p

-9

1

PDR

,

UaKTJMunafamCEUsusumuuMEDKTamam'iEOsD11@!gss2iELWJshsE'MhWK2r NAW@hATMEUF

~

-

_

g-- ' Form 374---- _------wm-mmmsatsfEE111MMf2FIsep_4m*FN*sswwsunsrrancaan. wag

I

'

U.S. NUCLEAR REGULATORY CoMMISSloN l

2

4

fI

l

NRC

.

pggg

g,

PAGES

License number

'E

I

50-19913-01

N

" """

UP LEM NTAR S E

30 9 1

,

g

Amendment No. 10

W

I

N

I

lN

N

N 9.

Authorized use

I

N

q A.

Any diagnostic procedure listed Groups I and II of Schedule A, Section 35.100

ly

l

of Title 10, Code of Federal Regulations.

(N

N

!E

N B.

Preparation and use of radiopharmaceuticals for any diagnostic procedure IJsted

I

in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal

!g

'

g

Regulations.

$

1

.

R

l C.

-In vitro studies.

.

.'

1

-

%

N

$,

k

D.

For blood flow and pulmonary' function studies.

'

l

E

E.

.

g

For treatment of polycythemia vera, leukemia and bone metastases.

g

'

l

E.

N

CONDITIONS

15;

4

-

lE:

q

cr

-

g:

10.

Licensedmaterial.'shallbeusedoni.yatKetchikahGeneralHospital,3100

l

!gj

g

Tongass Avenue, Ketchikan, Alaska;

'

+

i

-

, '

!>;

N 11.

The licensee shall-comply' with the . provisions _of Title 10, . Chapter 1, Code of

'E;

~ - . . . . -

-

R

Federal Regulatio'us, Part "19, " Notices,; Instructions and Reports [to Workers;

E!

I

Inspections" and Part 20, " Standards for Protection Againsti Radiation".

g 12.

Licensed material listed in Item 6.!above iscauthbrized for use b'y, or under the

h

'

q

supervision of, the4fo11owingiindividual(s) for'the ma'terials'and uses indicated:

il

g-

E;

s

,

'

4

Zeke L. Ifendricks , M.D. -

Groups I, II, and<III

E!

l

In vitro studies -

f

Xenon 133

J

gj

g

y

Phosphorus'32 as soluble phosphate for

gj

,

q

' treatment of polycythemia vera,

kj

'

i

' leukemia, and bone metastases

IEl

I

k

,

I

Arthur K. Ilarris, M.D.

Groups I, II, and III

ll

l

In vitro studies

g)

y

Xenon 133

gl

,

l

Phosphorus 32 as soluble phosphate for

N

I

treatment of polycythemia vera,

N

,

I

leukemia, and bone metastases

E

l

ll

l

'Rl

l

B

1

N

I

i

l

lN

I

'p

i

II

I

l

lI

I

k

n

,,

I

I)f

bm-mr-mrs_shidiaWWNC*MhiGDWhittsi.f2rJih2i0iLTJduQis0afaiDucs2ididsfW'#'u m M l

__-

-

- - - -

.

f

g

m 5c_mritT3GETElmlElmHT3GE2IIL3

-

l

NRC Porm 374A

U.S. NUCLEAR R gGULAToRY COMMISSloN

3

4

.

PAGE

og

PAGES

I

fE

l

License numtzt

I

50-19913-01

il

l

MATERIALS LICENSE

1

3,c y, , ,, g ,,,,,,,, ,, ,3,,

l

SUPPLEMENTARY SHEET

030-19521

1

N

l

Amendment No. 10

i

N

I

R

I

CONDITIONS

N

13.

For a period not to exceed sixty (60) days in any calendar year, a visiting

l

physician is authorized to use licensed material for human use uader the terms

!

lN

I

of this license, provided the visiting physician:

E'

l

R

l

(a) Has the prior written permission of the hospital's Administrator and its

f

g

Medical Isotopes Committee, and

Ig

i

IN

l

(b) Isspecificallynamedasauser[6naNuclear:RegulatoryCommissionlicense

I

ll

i

authorizing human use, and- '

E

g

-

s

y

,

W

(c) Performs only those- procedures for which he is specifically authorized by a

H

g

,y

y

Nuclear Regulatory Commission license,

i +

jg

W

,

-is

l5

g

The licensee shall maintain for inspection by the Commission,' copies of the

jN

4

written permissionfspecified in, subitem (a) above andL of the license (s)

il

M

specified in subitems (b) and1(c) above. These records shall be. maintained for

N

five (5) years from.the time:the-licensee grants its permission.under

'

('

Y

subitem (a) above. -

l

.

~

l

14.

The licensee is authorized to hold radioactive material with a physical

$

4

half-life of less;than 65 days for decay-in-storage before, disposal in ordinary

9

4

trash provided:

'

I

--

I

H ;

f

A.

Radioactive vaatie to' be disposed of in-tl$1stmanner shall be held for decay

k

g

a minimum of ten'(10) half-lives.

g

"

4

, s

W

4

B.

Prior to disposal.as normal waste,< radioactive-waste slall be monitored to

E!

3

E

I

determine that its' radioactivity cannot be distinguished from background

i

l'

with typical low-level laboratory survey instruments. All radiation labels

N

g

will be removed or obliterated.

-

f

'

N

~

-

%

'

l

C.

Generator columns shall be segregated'so"that they may be monitored

P{E

1

separately to ensure decay to background levels prior to disposal.

1

lN

j

l 15.

Effluent from the xenon 133 charcoal trap shall be tested for the presence of

f

g

xenon 133 after every ten patient procedures, in order to assure that the device

f

l

is functioning properly and that filter saturation has not occurred.

p

N

N 16.

The license shall include the reference standards described below when

R

performing dose calibrator accuracy tests:

i

g

Dose Calibrator Reference Standards

y

1

N

Radionuclide

Ac ti vi ty

Calibration Accuracy

!N

4

!i

fl

N

Cesium 137

90 microcuries or more

Within i 5%

l

il

Cobalt 57

One millicurie or more

Within i 5%

<

l.

I

if

I

il

brs ww-esshw

m ,r-r-r,==EN

7g

__

_ _ _ _ _ _

r==============_=*======~

_"3

U.S. NUCLEAR REGULATORY COMMISSION

lI

g

NRC Ferm 374A

.

PAGE

OF

PAGES

l

1icense numb 2r

.I

N

50-19913-01

!i

l

MATERIALS LICENSE

'N

oocket or nererence number

N

SUPPLEMENTARY SHEET

N

030-19521

I

E.

W

d

Amendment No. 10

g

I

t

!

I

l

CONDITIONS

I

l

q

170 Except as specifically provided otherwise in this license, the licensee shall

d

conduct its program in accordance with the statements, representations, and

j

4

procedures contained in the documents including any enclosures, listed below.

l

The Nuclear Regulatory Commission's regulations shall govern unless the

j

statements, representations and procedures in the licensee's application and

!g

g

correspondence are more restrictive than the regulations.

M

_

ju

I

A. Application dated October 27, 1981

p

,

4

B. Model ALARA Program contained in' Appendix O '

_

H

I

of Regulatory Guide 10.8.(Rev. 1)

N

l

C. Letter dated July 28, 1983

l

g

D. Letter dated September'29, 1983

g

E. Letter dated March 13, 1984

p

$

F. Telegram dated July 5, 1984

,g

i

G. Letter dated October 16, 1985

^

,

H. Letter dated November 19,l1985-

,

j l

1. Letter date.d December 20, 1985

i

l

y

,

y

J. Letter dated March 4,1986

"

N

,

d 18.

The Radiation Protection Officer for 'the activities authorized by this license

d

is Dr. Zeke L. Hendricks.

I

4

I

~

-

N

s

n

,

.

4

!

NI

'

ij

i

>

q

!

N

!

il

,

j

i

,f.

(

I

IP

i

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

d

!E

N

original signed by R. D. Thomas

N

Date March 10, 1986

By

g

j.

R. D. Thomas, Chief

g

l

Nuclear Materials Safety Section

g

N

Region V

l

4

E

I

g

i

I

l'l

1

p

I

>

I

i

!p

g

4

!g

l

ll

N

I

M

i

!g

i

'n

I

s

65LitwYw w 'i's2sm2sQrKT.zQswaMaBem TYacgMfir#2scr2m0#mWylwmXmisUiECE

ML20205Q854

Text

Navigation menu

Search